Shares of Viking Therapeutics jumped in morning trading after the company said that its VK2735 drug to tackle obesity is advancing to a phase 3.
The stock was up 28.25%, to $64.65, in morning trading on Thursday.
The clinical-stage biopharmaceutical company said that its first-half was marked by strong momentum in its pipeline program.
The phase 2 Venture study of VK2735 in obesity demonstrated up to an about 15% reduction in body weight following 13 weeks of dosing, as well as promising safety and tolerability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments